The ASX 200 company selling everything it makes due to its major competitor being out of the market: fundie

ResMed is performing strongly right now.

| More on:
A woman stands facing a set of shelves that is completely empty.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ASX healthcare share ResMed just reported a result which saw relatively strong growth
  • Fund manager Jun Bei Liu thinks the business has a good outlook
  • She called it a buy, particularly after a dip in the share price

S&P/ASX 200 Index (ASX: XJO) share ResMed Inc (ASX: RMD) is currently benefitting from the situation in its sector.

The ResMed share price has been on quite a journey during 2022. It fell by more than 20% from the start of the year to May 2022. However, since the May lows, it has gone up 20%. It's currently down around 7% in the calendar year.

While some businesses are struggling in the current environment with rising interest rates and elevated inflation, ResMed is one company that is still doing well. Part of that is down to a competitor having to recall its products.

In a recent profit update, the ASX healthcare share advised investors that for the three months to June 2022, its revenue increased by 4% and (net) income from operations increased by 6%.

The end of the fourth quarter meant that the business could tell investors about its full-year result for the 12 months to June 2022. Revenue increased by 12% to $3.6 billion and income from operations grew 11%.

After seeing that, one fund manager is bullish about the ASX share.

Jun Bei Liu, fund manager from Tribeca Alpha Plus Fund, spoke to Livewire about her thoughts on the business.

Expert's views on ResMed shares

Liu said the business' result was in line with expectations in terms of the earnings before interest and tax (EBIT), while operating profit was 4% better than expected.

One of the key highlights for Tribeca was that United States device sales were "incredibly strong" (with 11% growth) even though it's cycling against strong growth in the prior year.

Jun Bei Liu said that gross profit was "okay" from the ASX 200 share and in line with expectations, while cash flow was "just a tad weaker". She explained the positive reason for that to Livewire:

It's mainly because they do need to build some inventory. The demand has been so strong they're just selling everything they build. They had to build a little bit of inventory just to sell through different channels.

What is the outlook for ASX healthcare share?

The fund manager likes ResMed shares and the wider healthcare sector because it's "very defensive" and has structural growth. She doesn't think that earnings will be hurt by economic uncertainty.

Tribeca thinks that ResMed's outlook is "very bullish". She pointed out that, on an earnings call, management talked about increasing production quarter on quarter, which she called "very strong", partly due to the issues faced by Phillips, its competitor. ResMed management reportedly indicated that Phillips "won't come back into the market for at least another 12 months". She said that's really good for ResMed.

Liu also pointed out that ResMed has strong pricing power, which it can use to offset the inflation on the costs side of the business.

Is the ResMed share price an opportunity?

The fund manager said to Livewire:

I would buy this stock, particularly when it has a dip on a result that is very strong, and it is giving a very bullish outlook for the next 12 months as well.

She also said that the 5% fall for the company on the day of the report was an "overreaction".

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »